心不全における人工知能誘導神経調節:メカニズム,証拠,将来の方向
Rabiah Aslam Ansari1, Sidhartha Gautam Senapati2, Vibhor Ahluwalia3
1Digital Engineering & Artificial Intelligence Laboratory (DEAL), Department of Critical Care Medicine, Mayo Clinic, Jacksonville, FL 32224, USA.
Journal of cardiovascular development and disease
|August 27, 2025
まとめ
人工知能 (AI) は,心不全 (HF) の管理のための自律神経調節を強化します. AIによる戦略は,心不全の減少エジェクション分数 (HFrEF) と保存されたエジェクション分数 (HFpEF) の両方を改善し,患者の選択をパーソナライズします.
科学分野:
- 心臓病科
- 生物医学工学
- 人工知能
背景:
- HFrEFとHFpEFを含む心不全 (HF) は,HFpEFの有効な治療法が限られている世界的な健康上の課題です.
- 両方のHF型は高度の再入院率と生活の質の低下をもたらします 特に併発性疾患を持つ高齢者の場合です
研究 の 目的:
- 心不全の改善のための自律神経調節を促進する 人工知能 (AI) の役割を検討する.
- 異なるHF現象型のための神経調節療法をパーソナライズするAIの可能性を調査する.
主な方法:
- 心不全に対する自律神経調節におけるAI応用に関する現在の文献のレビュー.
- 患者の選択,刺激戦略の最適化,適応型閉ループシステムのAIの役割の分析.
- HFpEFのAI駆動深層フェノタイプ化とHFrEFのダイナミック刺激調整の検討
主要な成果:
- AIは患者の選択を強化し,心不全における自律神経調節のための刺激戦略を最適化します.
- AI駆動の適応システムは,HFrEFに対する生理学的フィードバックに基づいて神経調節を動的に調整します.
- AIは,神経調節介入に反応する患者のサブグループを特定するために,HFpEFの深いフェノタイプ化を容易にする.
結論:
- AIによる自律神経調節は パーソナライズされたデータに基づく 心不全の治療戦略を提供します
- データ統合,倫理的な監督,臨床採用の課題に対処することは,HFにおける現実世界のAIアプリケーションにとって極めて重要です.
- 患者中心の心不全のケアにおいて 分野間の協力と倫理的なイノベーションが不可欠です
関連する概念動画
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:26Heart Failure Drugs: Inotropic Agents
717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:29Heart Failure II: Pathophysiology
37
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
37
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
01:27Heart Failure I: Introduction
52
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
52